Biennier Salomé, Fontaine Mathieu, Duquenoy Aurore, Schwintner Carole, Doré Joël, Corvaia Nathalie
MaaT Pharma, 69007 Lyon, France.
Université Paris-Saclay, INRAE, MetaGenoPolis, AgroParisTech, MICALIS, 78350 Jouy-en-Josas, France.
Microorganisms. 2024 Nov 7;12(11):2256. doi: 10.3390/microorganisms12112256.
This review explores the complex relationship between gut dysbiosis and hematological malignancies, focusing on graft-versus-host disease (GvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We discuss how alterations in microbial diversity and composition can influence disease development, progression, and treatment outcomes in blood cancers. The mechanisms by which the gut microbiota impacts these conditions are examined, including modulation of immune responses, production of metabolites, and effects on intestinal barrier function. Recent advances in microbiome-based therapies for treating and preventing GvHD are highlighted, with emphasis on full ecosystem standardized donor-derived products. Overall, this review underscores the growing importance of microbiome research in hematology-oncology and its potential to complement existing treatments and improve outcomes for thousands of patients worldwide.
本综述探讨了肠道菌群失调与血液系统恶性肿瘤之间的复杂关系，重点关注异基因造血干细胞移植（allo-HSCT）受者的移植物抗宿主病（GvHD）。我们讨论了微生物多样性和组成的改变如何影响血液癌症的疾病发展、进展和治疗结果。研究了肠道微生物群影响这些病症的机制，包括免疫反应的调节、代谢产物的产生以及对肠道屏障功能的影响。强调了基于微生物组的治疗和预防GvHD的最新进展，重点是全生态系统标准化的供体来源产品。总体而言，本综述强调了微生物组研究在血液肿瘤学中日益重要的地位及其补充现有治疗方法并改善全球数千名患者治疗结果的潜力。
